Presentation TCT 2015 The Evolving CMS Reimbursement Process: How Can CMS Promote Innovation, and What Clinical Data Make a Difference? Presenter: James Rollins October 13, 2015 REGISTER for free or LOG IN to view this content Presentation TCT 2015 Up Next Presentation TCT 2015 SORT-OUT VI: A Prospective Randomized Trial of a Durable-Polymer Zotarolimus-Eluting Stent Versus a Bioabsorbable-Polymer Biolimus-Eluting Stent in Patients With Coronary Artery Disease Three-Year Outcomes Presenter: Bent Raungaard October 13, 2015 More slides + Presentation TCT 2015 TCT 81: Six Versus 12 Months of Dual Antiplatelet Therapy After Implantation of Biodegradable-Polymer Sirolimus-Eluting Stent A Randomized Substudy of the I-LOVE-IT 2 Trial Presenter: Yaling Han October 13, 2015 Presentation TCT 2015 From COURAGE and BARI 2D to ISCHEMIA: What Answers Can We Expect (and Not Expect) From ISCHEMIA? Presenter: Sripal Bangalore October 11, 2015 We Recommend
Presentation TCT 2015 SORT-OUT VI: A Prospective Randomized Trial of a Durable-Polymer Zotarolimus-Eluting Stent Versus a Bioabsorbable-Polymer Biolimus-Eluting Stent in Patients With Coronary Artery Disease Three-Year Outcomes Presenter: Bent Raungaard October 13, 2015
Presentation TCT 2015 TCT 81: Six Versus 12 Months of Dual Antiplatelet Therapy After Implantation of Biodegradable-Polymer Sirolimus-Eluting Stent A Randomized Substudy of the I-LOVE-IT 2 Trial Presenter: Yaling Han October 13, 2015
Presentation TCT 2015 From COURAGE and BARI 2D to ISCHEMIA: What Answers Can We Expect (and Not Expect) From ISCHEMIA? Presenter: Sripal Bangalore October 11, 2015